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Abstract
Purpose—The promise of precision oncology is that identification of genomic alterations will 
direct the rational use of molecularly targeted therapy. This approach is particularly applicable to 
neoplasms that are resistant to standard cytotoxic chemotherapy, like T-cell leukemias and 
lymphomas. In this study, we tested the feasibility of targeted next-generation sequencing in 
profiles of diverse T-cell neoplasms and focused on the therapeutic utility of targeting activated 
JAK1 and JAK3 in an index case.
Patients and Methods—Using Foundation One and Foundation One Heme assays, we 
performed genomic profiling on 91 consecutive T-cell neoplasms for alterations in 405 genes. The 
samples were sequenced to high uniform coverage with an Illumina HiSeq and averaged a 
coverage depth of greater than 500× for DNA and more than 8M total pairs for RNA. An index 
case of T-cell prolymphocytic leukemia (T-PLL), which was analyzed by targeted next-generation 
sequencing, is presented. T-PLL cells were analyzed by RNA-seq, in vitro drug testing, mass 
cytometry, and phospho-flow.
Results—One third of the samples had genomic aberrations in the JAK-STAT pathway, most 
often composed of JAK1 and JAK3 gain-of-function mutations. We present an index case of a 
patient with T-PLL with a clonal JAK1 V658F mutation that responded to ruxolitinib therapy. 
After relapse developed, an expanded clone that harbored mutant JAK3 M511I and 
downregulation of the phosphatase, CD45, was identified. We demonstrate that the JAK missense 
mutations were activating, caused pathway hyperactivation, and conferred cytokine 
hypersensitivity.
Conclusion—These results underscore the utility of profiling occurrences of resistance to 
standard regimens and support JAK enzymes as rational therapeutic targets for T-cell leukemias 
and lymphomas.
INTRODUCTION
T-cell neoplasms are known for their clinically aggressive behavior and for their high risk of 
relapse and resistance to conventional cytotoxic regimens. Adult patients with precursor 
neoplasms, such as acute T-cell lymphoblastic leukemia (T-ALL), or with mature neoplasms, 
such as T-cell non-Hodgkin lymphoma (T-NHL), have a 5-year survival rate of 20% to 30% 
even after intensive multiagent chemotherapy.1–6 There are rare exceptions to these dismal 
outcomes, such as children and adolescents who have T-ALL or anaplastic large-cell 
lymphoma (ALCL) with unique gene rearrangements (ie, ALK positivity or DUSP22 
positivity) in whom 5-year survival rates are greater than 70% to 80% with similar 
chemotherapy regimens.5,7,8 However, relapsed disease is challenging to cure. Clearly, novel 
therapeutic approaches are needed, and the development of commercially available next-
generation sequencing has raised the possibility that genomically directed therapy may be 
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applied to T-cell leukemias and lymphomas. Genomic profiling has been performed on 
several histopathologic subtypes of T-cell leukemias and lymphomas to better characterize 
the molecular genetics.9–13 Interestingly, recent genomic profiling has discovered frequent 
aberrations within the Janus kinase (JAK)–signal transducer and activator of transcription 
(STAT) pathway in both precursor (T-ALL) and mature (T-NHL) T-cell neoplasms, which 
suggests that JAK kinase inhibition may be important therapeutically.14
JAKs are encoded by four paralogous genes, JAK1, JAK2, JAK3, and TYK2. These tyrosine 
kinases are recruited to cytokine receptors, where they transduce signals by phosphorylation 
of key substrates—most important, STAT proteins that bind DNA and regulate gene 
expression. JAK1 mutations have been found in 10% of childhood T-ALLs.15 Our laboratory 
and others have found JAK3 mutations in cutaneous T-cell lymphoma (CTCL), adult T-cell 
leukemia/lymphoma (ATLL), T-cell prolymphocytic leukemia (T-PLL), and natural killer/T-
cell lymphoma (NKTL).16–20 Analyses of human leukemia lines and mouse models show 
that JAK mutations typically are activating and cause constitutive signal transduction, which 
may be blocked by tyrosine kinase inhibitors. Two such ATP-competitive inhibitors have 
been approved by the US Food and Drug Administration (FDA) for human use. Ruxolitinb 
is approved for use in myeloproliferative neoplasms, and tofacitinib is approved for 
rheumatoid arthritis.21,22
In this study, we deployed a commercially available hybrid-capture/next-generation 
sequencing platform to characterize major recurrent oncogene and tumor suppressor 
aberrations in 91 T-cell neoplasms. This targeted approach found that 33% of samples had 
JAK-STAT abnormalities, which included missense mutations in JAK1 and JAK3, 
rearrangements in JAK2 and JAK3, and missense mutations and amplifications of STAT3 
and STAT5. We analyzed an index case of T-PLL, a deadly mature T-cell neoplasm with 
both JAK1 and JAK3 gain-of-function missense mutations.23 This patient with T-PLL had 
experienced progression during multiple lines of chemotherapy but experienced disease 
response with ruxolitinib, a JAK1/2 inhibitor. The patient eventually experienced relapse as 
a result of clonal expansion of T-PLL cells with gain of function of JAK3 and 
downregulation of CD45. To our knowledge, this study is the first to demonstrate an in vivo 
response to ruxolitinib in a T-cell neoplasm, which underscores the importance of the 
interleukin-2 receptor gamma chain IL2RG/JAK1/JAK3 cytokine pathway in the 
pathogenesis of T-cell neoplasms and supports inhibition of JAK enzymes as therapy.
PATIENTS AND METHODS
Patient Samples, Processing, Sequencing
Patient peripheral blood or bone marrow was banked after informed consent under a 
protocol approved by the Vanderbilt institutional review board. Workflows have been 
described as the commercially available Foundation One and Foundation One Heme assays. 
DNA and RNA samples were extracted from fresh liquid specimens (blood or bone marrow 
aspirate). Adaptor-ligated libraries were created from DNA and cDNA as described.24 
Libraries were sequenced on Illumina HiSeq2500 (Illumina, San Diego, CA) to > 500× 
coverage depth for DNA and > 8M total pairs for RNA. DNA and RNA sequence data were 
processed with a customized analysis pipeline designed to accurately detect multiple classes 
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of genomic alterations—specifically, base substitutions, indels, focal gene amplifications, 
homozygous gene deletions, gene fusions, and genomic rearrangements (Data Supplement).
24
Gene Expression
The RNA sequencing workflow has been described previously. It also is detailed in the Data 
Supplement.25
Antibodies and Staining
See the Data Supplement for lists of antibodies used in this study. Cell staining also is 
described in Data Supplement.
Mass Cytometry and Phospho-Flow
Samples were stained and prepared for the mass cytometer as previously described. A 
description also is in the Data Supplement.26
Phosphatase Enzyme Assay and Inhibitor Studies
Frozen pre- and post-treatment T-PLL cells and Jurkat cells were lysed in hypotonic buffer 
and prepared with cytosol, as described.27 Ruxolitinib and tofacitinib were purchased from 
Selleck Chemicals (Houston, TX), and working solutions were prepared in dimethyl 
sufoxide (DMSO). T-PLL cells were plated in RPMI/10% fetal calf serum and treated with 
DMSO alone or with various concentrations of drug. Cell viability was quantified with a 
CyQuant assay (Invitrogen, Carlsbad, CA), as described.17,27 Statistical analyses were 
performed with GraphPad Prism (La Jolla, CA).
RESULTS
Genomic Profiling of T-Cell Leukemias and Lymphomas
We analyzed 91 occurrences of diverse T-cell leukemias and lymphomas for alterations in 
405 cancer-causing genes by comprehensive hybrid capture of genomic DNA followed by 
next-generation sequencing (Data Supplement). On the basis of the WHO classification 
scheme, the cohort was composed of 25 precursor T-cell neoplasms (ie, T-ALL, acute 
lymphoblastic leukemias) and 66 mature T-cell neoplasms (ie, angioimmunoblastic 
lymphoma [AITL; n = 8], ALCL [n = 7], CTCL [n = 14], peripheral T-cell lymphoma 
[PTCL; n = 16], T-cell large granular leukemia [T-LGL; n = 11], T-PLL [n = 7], and NK/TL 
[n = 3]). The cohort showed a marked male predominance for both immature and mature T-
cell neoplasms (4:1 and 1.75:1, respectively; Data Supplement) consistent with the 
epidemiology of these cancers.28,29 Samples were sequenced at a mean exon depth of ×489 
by Illumina HiSeq. As shown in Figure 1 and the Data Supplement, the most common gene 
alterations was CDKN2A/B, followed by TET2, NOTCH1, JAK3, TP53, STAT3, NRAS, 
DNMT3A, JAK1, RHOA, MLL2, and others.
The frequencies of gene alterations were compared between immature (T-ALLs) and mature 
T-cell neoplasms: NOTCH1 (48% v 3%, P < .001), FBXW7 (16% v 1.5%, P = .0191), and 
NRAS (24% v 4.5%, P = .0117) mutations were more frequent among T-ALL than mature 
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T-cell neoplasms. STAT3 mutations (0% v 18%, P = .032) were more common in mature T-
cell neoplasms (Table 1); 31.8% (29 of 91 samples) had alterations in the JAK-STAT 
pathway. JAK3, which involved 13% (12 of 91 samples) of samples, was the most 
commonly mutated kinase, followed by JAK1, which was mutated in 7.7% (seven of 91 
samples). There were two occurrences of JAK2 rearrangement (n = 1 each in CTCL and T-
ALL) and five occurrences of ABL1 rearrangements (n = 1 CTCL, n = 1 T-PLL, and n = 4 
T-ALL). JAK3 mutations were present with a similar frequency in T-ALL and in mature T-
cell neoplasms (Fisher's exact test, P = .19) but were highly frequent in certain mature T-cell 
neoplasms, such as T-PLL (five [71%] of seven samples). Interestingly, all five occurrences 
of T-PLL had the M511I JAK3 mutation; all of the JAK3 and JAK1 mutations were in the 
Catalogue of Somatic Mutations in Cancer (COSMIC; http://cancer.sanger.ac.uk/cosmic) 
database, frequently within the pseudokinase domains of the proteins (Fig 2).30 JAK3 
missense mutations have been identified previously in CTCL and ATL.16 Focal STAT3, 
STAT5A, and STAT5B amplifications were identified in two occurrences (n = 1 each in 
CTCL and ALCL), in addition to missense mutations within the SH2 domains of STAT3 and 
STAT5B, such as STAT3 D661Y/V in T-LGL (Fig 2). STAT5 and STAT3 gene alterations 
were mutually exclusive with JAK1 or JAK3 mutations. PTCL6 had mutations in STAT3 and 
JAK1 at 7% allele frequencies, respectively, and likely were separate clones. JAK1 and 
JAK3 mutations were observed in the same tumor in five occurrences, but concordant 
mutations in the same cell could not be confirmed (Data Supplement). JAK3 mutations were 
concordant with mutations in TP53 in four samples; NOTCH1 mutations, in four samples; 
and CDKN2A deletions, in three samples (Data Supplement).
Exceptional Response of a JAK1-Mutant T-PLL
We evaluated a 62-year-old woman in our clinic with relapsed T-PLL. She presented with 
constitutional symptoms, splenomegaly, and leukemic blood counts that had increased to 
greater than 150,000/μL and progressed through alemtuzumab; cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP); romidepsin; and pralatrexate. The T-PLL 
cells were CD2+CD3+CD4+CD7+CD8−CD56−CD57− (Fig 3A), had clonal T-cell receptor 
rearrangement (data not shown), and had infiltration of bone marrow (Figs 3B through 3E). 
The T-PLL cells (90% of peripheral-blood mononuclear cells) were analyzed by hybrid 
capture followed by next-generation sequencing. As shown in Figure 3F, the T-PLL cells had 
a JAK1 V658F mutation at 40% allele frequency and a JAK3 M511I mutation at 5%. Other 
notable mutations were in ATM and TP53 at allele frequencies of 92% and 78%, 
respectively, which suggests loss of heterozygosity (Data Supplement). Both JAK1 and 
JAK3 mutations had been described in hematologic malignancies and have proven to be 
oncogenic in various assays.20,30–32 The clonal JAK1 mutation could be targeted by 
ruxolitinib, a kinase inhibitor with activity against JAK1/2.21 The patient was agreeable to 
this off-label therapy and received 20 mg twice daily; her peripheral count (90% T-PLL) 
declined from 142,000/μl to 85,000/μl within 5 days. By day 7 day, her spleen, which was 
palpable at 4 cm below the costal margin before therapy, was no longer palpable. She 
experienced no adverse effects from ruxolitinib, and her leukocyte count stabilized to 
approximately 60,000/μL for more than 110 days. During the 100 days before ruxolitinib 
therapy, the patient required 10 apheresis units of platelets and 7 units of packed red blood 
cells; conversely, during ruxolitinib therapy, she received 3 apheresis units of platelets and 2 
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units of packed red blood cells. Unfortunately, by day 116, the leukemic blood count 
increased to 116,000/μL, and a bone marrow biopsy confirmed relapsed disease (Fig 3G). 
The patient developed worsening thrombocytopenia that did not respond to cytotoxic 
chemotherapy, and she died as a result of the disease. Acquired resistance to ruxolitinib and 
the pan-JAK inhibitor, tofacitinib, was cell intrinsic, because it was observed ex vivo. 
Pretreatment T-PLL cells were more sensitive to ruxolitinib (50% inhibitory concentration 
[IC50], 3.85 × 10−8 M) and tofacitinib (IC50, 8.64 × 10−8 M) compared with post-treatment 
cells (post-ruxolitinib IC50, 4.21 × 10−7 M; post-tofacitinib 50IC50, 2.86 × 10−6 M; P < .
001; Fig 3H).
Genetic and Immunophenotypic Analysis of Resistance to Ruxolitinib Therapy
At relapse, the JAK3 M511I allele frequency had increased from 5% to 28%, whereas the 
allele frequency of JAK1 V658F had decreased from 40% to 18% in the T-PLL cells (Fig 
3F). TP53, ATM, and other mutational frequencies did not change (Data Supplement). The 
pre- and post-ruxolitinib T-PLL cells were analyzed by RNA sequencing, in which the 
steady state abundance of mutant mRNAs approximated the allele frequencies (Data 
Supplement). The pre- and post-ruxolitinib/relapse T-PLL cells were analyzed for 28 cell 
surface antigens by mass cytometry. The multidimensional staining pattern was analyzed by 
viSNE, an algorithm that maps cells on to a two-dimensional plot.33 Peripheral-blood 
mononuclear cells from healthy donors were stratified into distinct cell populations that 
corresponded to specific lineages: CD4+/CD8+ T cells, natural killer cells, macrophages, and 
B cells (Fig 4A). The T-PLL cells from the patient case were clustered into a unique island 
composed of 95.3% total peripheral cells and few nonmalignant cell types (Fig 4A). The 
sample after relapse occurred showed two distinct leukemic populations (Figs 4A and 4B): 
one which resembled the pre-ruxolitinib sample (46.1%), and a new island that emerged 
with drug resistance (50.6%). CD45 protein expression was the major feature that 
discriminated the two relapsed cell populations (Figs 4C through 4D). The CD45+ 
population resembled the pretreatment cells except for reduced expression of CD127 
(interleukin 7 receptor [IL-7R]). The CD45lo/− population showed increased CD27 
(TNFRSF7), CD44 (H-CAM), CCR4, and CCR7 and reduced CD43 (leukosialin) compared 
with pre- or post-treatment CD45+ cells (Figs 4C through 4D).
CD45 is a receptor tyrosine phosphatase encoded by the PTPRC gene that negatively 
regulates JAK-STAT and T-cell receptor signaling.34,35 CD45 downregulation coincident 
with clinical relapse on ruxolitinib implied that it may be a mechanism for ruxolitinib 
resistance. The JAK1 mutation was not detectable by Sanger sequencing, but the JAK3 
mutation was clonal and present in CD45hi, CD45intermediate, and CD45− cells (Figs 5A and 
5B). CD45RO and CD45RB were the mRNA isoforms expressed by the T-PLL cells (via 
RNA sequencing and flow cytometry; Data Supplement). Whole-transcriptome analysis on 
pre- and post-treatment samples found that PTPRC mRNA abundance was reduced 
significantly in the relapsed sample by 1.95-fold (P = 3.18E−74; Fig 5D), which 
approximates the 50% reduction in protein levels observed by flow cytometry. JAK1, JAK2, 
and JAK3 mRNAs also were downregulated significantly (Fig 5D). JAK1 and JAK3 were 
probed by Western blot analysis of whole-cell lysates and showed lower protein abundance 
in the relapsed sample compared with lysates before ruxolitinib treatment (Fig 5C).
Greenplate et al. Page 6
JCO Precis Oncol. Author manuscript; available in PMC 2019 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Next, the tyrosine phosphatase activity was analyzed in lysates prepared from T-PLL cells 
pre- and post-ruxolitinib/relapse therapy. Immuno-depletion with a specific antibody against 
CD45 reduced total tyrosine phosphatase activity to 20% to 22% of normal, which 
confirmed that CD45 was the major enzyme to contribute to this enzyme activity in T-PLL 
cells (Fig 5E). The specific activity of tyrosine phosphatase in pre-ruxolitinib lysates was 
3.40 μmol/min/mg (95% CI, 3.10 to 3.70 μmol/min/mg), which decreased 54% to 1.85 
μmol/min/mg (95% CI, 1.58 to 2.12 μmol/min/mg) in the post-ruxolitinib/relapse sample (P 
< .001; Fig 5F). Thus, the cellular phosphatase activity reflected the decreased CD45 protein 
levels, which paralleled the decrease in PTPRC mRNA abundance. Interestingly, there was 
another T-PLL case with a JAK3 M511I mutation that had downregulated CD45 at the time 
of disease relapse after treatment with combination cyclophosphamide, doxorubicin, 
vincristine, and prednisone chemotherapy (Data Supplement).
Enhanced Phosphorylations Downstream of JAK1/JAK3 at Relapse
CD45 has been shown to directly dephosphorylate JAK1 and JAK3, which suggests that its 
loss of function should show increased activity of JAK3 or JAK1. To analyze JAK activity, 
we probed the intracellular phosphorylation of key substrates in T-PLL cells pre- and post-
ruxolitinib/relapse treatment by flow cytometry. The percentage of T cells that expressed 
basal levels of phospho-STAT1 (p-STAT1) and p-STAT5 were increased in pre-ruxolitinib 
cells and in post-ruxolitinib/relapse cells compared with healthy T cells (p-STAT1: 22.72% 
and 21.24%, respectively, v 0.79%; p-STAT5: 57.52% and 54.84%, respectively, v 2.21%), 
whereas no cells in any condition expressed basal phosphorylation of p-STAT6, which 
served as a control (Fig 6B). T-PLL cells with the lowest expression of CD45 had the 
highest proportion of p-STAT5–positive cells at baseline before any stimulation (Fig 6C). To 
assess whether T-PLL cells had increased sensitivity to cytokine stimulation in addition to 
increased basal signaling, we stimulated each sample with 20 ng/mL of cytokine for 15 
minutes. Signaling was quantified as previously described36,37 by using the median 
fluorescence intensity of per-cell phosphoprotein to create a fold-change. Increased 
phosphorylation of STAT5 was seen after in vitro stimulation with IL-2, IL-4, IL-7, IL-21, 
and interferon gamma, but not with IL-9, in both pre- and post-ruxolitinib/relapse–treated 
samples compared with healthy T cells (Fig 6D). A comparison between pre- and post-
ruxolitinib/relapse T-PLL cells showed similar p-STAT5 levels at baseline and after 
stimulation by cytokines (Fig 6D). For example, there was an IL-2–induced 1.49-fold 
change in p-STAT5 for pre-ruxolitinib samples and 1.44-fold (comparison of arcsine 
transformed raw values) change for post-ruxolitinib/relapse samples. To understand the 
effects of CD45 expression, we gated on CD45hi, CD45lo, and CD45− post-ruxolitinib/
relapse T-PLL cells and analyzed p-STAT5 and p-STAT6 basally and in response to stimuli. 
CD45hi had the lowest p-STAT5 response to IL-2 (0.23-fold), followed by CD45lo (0.61-
fold) and CD45− (1.24-fold; Fig 6D); this pattern was seen for all common gamma chain 
cytokines compared with control (p-STAT6; Figs 6D and 6E). In summary, T-PLL cells were 
hyper-responsive to common gamma chain cytokines, and CD45 expression was negatively 
correlated with p-STAT5 at relapse.
Greenplate et al. Page 7
JCO Precis Oncol. Author manuscript; available in PMC 2019 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DISCUSSION
In this study, diverse T-cell neoplasms were pro-filed by targeted next-generation sequencing 
of the exomes from approximately 400 known tumor suppressors and oncogenes. Among 
oncogenic mutations, JAK-STAT (33%) alterations were the most common. The cohort was 
composed of occurrences submitted to Foundation Medicine as a result of relapsed or 
resistant disease, so the observed genetic alterations may be specific to advanced-stage 
disease or therapeutic resistance. Nevertheless, the mutation frequencies for JAK3 (13% of 
occurrences) and for JAK1 (8.7%) were consistent with genomic profiling studies focused 
on specific disease subtypes (ie, T-ALL, ATLL, T-PLL, and CTCL15–19; less often, AITL 
and PTCL).38,39 The JAK mutations in this study were mutually exclusive with STAT3 and 
STAT5 gene alterations, as expected, because STAT3 and STAT5 proteins are downstream of 
IL2RG (common gamma chain)/JAK1/JAK3–restricted cytokines. Interestingly, recent data 
in cell lines and mouse models suggest that JAK1 enzyme activity is required for mutant 
JAK3 effects.40–42 However, as in the index case, the mutations were co-occurring but not 
present in the same cell; allele frequencies approached 50% for JAK1 and JAK3 mutations 
in the same tumor.
Most important, the JAK1 and JAK3 mutations were functionally significant, because they 
induced constitutive phosphorylations of downstream STAT5 proteins. p-STAT3 was not 
observed in the T-PLL cells (data not shown), although it is an important downstream 
substrate in other T-cell neoplasms, such as ALCL.43 Thus, signaling patterns downstream 
of JAK1/JAK3 may be unique to disease subtype. STAT1 and STAT5 phosphorylations in T-
PLL could be inhibited by the specific JAK inhibitors ruxolitinib and tofacitinib.44 In the 
index case, treatment with ruxolitinib induced an impressive clinical response. These 
compelling data argue for oncogene dependence upon the JAK-STAT pathway in T-PLL, 
results that may extend to other T-cell neoplasms with JAK mutations. Furthermore, this oral 
drug worked when intensive parenteral therapies had failed to control the disease.
This study showed two cell-intrinsic mechanisms to account for resistance to ruxolitinib: 
expansion of the mutant JAK3 T-PLL clone and downregulation of CD45. In in vitro studies, 
the IC50 of ruxolitinib for JAK1 is 3.3 nM; for JAK2, it is 2.8 nM45; and for JAK3, it is 428 
nM.45 This diminished potency against JAK3 probably accounted for the expansion of the 
mutant JAK3 clone from 10% before ruxolitinib to 56% at relapse. The T-PLL cells showed 
cross-resistance to tofacitinib, which has a nanomolar IC50 for JAK3.46,47 The 
downregulation of CD45 protein appears to be an additional resistance mechanism at 
relapse. Reduced CD45 proteins reduced the total tyrosine phosphatase activity in the T-PLL 
cells, which correlated with increased p-STAT5. PTPRC mRNA abundance was decreased, 
which suggests either enhanced mRNA degradation or transcriptional repression. The 
expression pattern of CD45 in a clonal T-PLL population resembles position-effect 
variegation, an epigenetic phenomenon.48,49 Because the primary leukemia samples were 
consumed, we were unable to directly transduce PTPRC cDNA to test if JAK inhibitor 
sensitivity could be restored. Thus, a cooperative genetic interaction between PTPRC loss of 
function and JAK3 M511I remains speculative. We observed an additional case of T-PLL 
with a clonal JAK3 M511I mutation that had similarly downregulated CD45 after disease 
relapse during CHOP chemotherapy, which suggests that downregulation of the CD45 
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protein may play a role in chemotherapy resistance. Notably, Porcu et al50 discovered 
deletion, missense, and nonsense mutations in PTPRC in T-ALL—evidence that supports a 
tumor suppressor role for PTPRC in this disease. Furthermore, Porcu et al50 also showed 
concordant loss of function in PTPRC and gain of function in JAK1 or IL7R, which suggests 
that these two hits cooperate in T-ALL pathogenesis. In fact, the authors described 
augmented p-STAT5 when PTPRC was knocked down by small interfering RNA. Our 
studies on the index case are similar to these findings, because we also observed an inverse 
correlation between CD45 levels and p-STAT5, albeit in T-PLL. Our studies do suggest that 
PTPRC may be a tumor suppressor in more mature T-cell neoplasms in addition to precursor 
T-ALL and that its loss of function may be an important resistance mechanism to ruxolitinib. 
Finally, the data presented in this study support the design of larger phase I/II clinical trials 
to test ruxolitinib on its own or in combination with cytotoxic therapies in T-cell neoplasms. 
A basket design in which patients with rare T-cell subtypes may be enrolled on the basis of 
the presence of JAK1 or JAK3 mutations may be most informative.
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Fig 1. 
Targeted next-generation sequencing of T-cell neoplasms. (A) Bar graph shows the 
frequency of genetic aberrations (color coded) in 91 samples of T-cell leukemias or 
lymphomas. The y-axis shows the percentage of total samples. (B) Tile plot shows recurrent 
genetic aberrations in all 91 samples. Lines bracket immature T-cell neoplasms (T-cell acute 
lymphoblastic leukemias [T-ALLs]). The x-axis shows the T-cell neoplasm subtype of each 
individual sample: angioimmunoblastic T-cell lymphoma (AITL); anaplastic large-cell 
lymphoma (ALCL); cutaneous T-cell lymphoma (CTCL); natural killer/T-cell (NKT) 
lymphoma; peripheral T-cell lymphoma (PTCL); T-ALL; T-cell large granular leukemia (T-
LGL); and T-cell prolymphocytic leukemia (T-PLL). The y-axis shows genes with boxes 
colored blue for substitution/insertions or deletions (indels), gold for gene amplifications, 
gray for homozygous deletions, dark red for truncations, and dark blue for gene fusions or 
rearrangements (as noted in A).
Greenplate et al. Page 15
JCO Precis Oncol. Author manuscript; available in PMC 2019 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig 2. 
Frequent missense mutations in JAK1, JAK3, STAT5B, and STAT3. Schematic shows 
protein domain structures of JAK3, JAK1, STAT5B, and STAT3. Black lines under the 
schematics show exon numbers above and amino acid numbers below; JAK3 exons are not 
shown because of differential splicing. Missense mutations are denoted by blue circles, with 
codon changes as shown. α, alpha helical domain, a DNA binding domain; FERM, the 
conserved domain named for its founding members (band 4.2, ezrin, radixin, and moesin); 
JH1, JAK homology domain 1, the functional kinase domain; JH2, JAK homology domain 2 
(also known as the pseudokinase domain); SH2, Src homology domain 2; STAT-int, STAT 
interaction domain.
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Fig 3. 
A case of T-cell prolymphocytic leukemia (T-PLL) that responded to specific JAK1 
inhibitor, ruxolitinib. (A) Dot plots show the immunophenotype of the T-PLL cells at 
presentation as analyzed by flow cytometry; T-PLL cells were interpreted as TdT− CD1− 
CD3+ CD5+ CD7+ CD4+. Photomicrographs of (B) peripheral-blood smear and (C) bone 
marrow biopsy that shows marked hypercellularity. Bone marrow aspirates (D) with 
homogeneous cells and (E) at high power, which shows neoplastic cells with fine chromatin 
and prominent nucleoli. (F) Foundation One panel analysis of T-PLL cells before (pre-RX) 
and after (post-RX) ruxolitinib treatment. Major gene mutations are shown with their major 
allele frequencies and the number of reads. For example, JAK1 V658F was present in the 
pre-RX sample at 40% supported by 772 reads. (G) Plot of the total leukocytes for the 
patient; y-axis shows cells number (×103); gray brackets show the normal range of 
peripheral leukocyte number. The x-axis shows time in days with some clinical features 
highlighted. Dark blue arrows, time points of physical exams that show a palpable spleen 4 
cm below costal margin before ruxolitinib therapy; spleen mass was not palpable after 
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treatment. Dark gold arrows, time of first Foundation One analysis, the start of ruxolitinib 
therapy, and the Foundation One Heme panel analysis at relapse. (H) Bar graphs of T-PLL 
cells treated in vitro with varying concentrations of ruxolitinib (left panel) or tofacitinib 
(right panel) in molar (M) quantities; the y-axis shows cell viability. Blue bars, pre-RX 
samples; gold bars, post-RX/relapse samples. Error bars are standard error of the mean for 
three independent experiments.
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Fig 4. 
CyTOF analysis shows marked change in immunophenotype of T-cell prolymphocytic 
leukemia (T-PLL) cells after relapse from ruxolitinib. Peripheral-blood samples from a 
healthy donor and the patient with T-PLL, before ruxolitinib (pretreatment) and at relapse 
(post-treatment) were analyzed by mass cytometry after staining for 28 cell surface markers. 
(A) viSNE analysis performed on the data to allow grouping of peripheral leukocytes into 
distinct islands that correspond to (B) cell lineages; iridium (DNA intercalator)-positive (Ir+) 
events show those cells that were intact. (C) The level of expression of 12 cell surface 
markers in the distinct islands. (D) The same 12 markers in the post-RX sample. High-
dimensional, single-cell immunophenotype was measured with a 28-marker mass cytometry 
panel. (A) The viSNE map shows cell density for all Ir+ (nucleic DNA intercalator) cells 
from a healthy donor and in pretreatment and post-treatment/relapse cells. (B) Cellular 
identity of each island was identified by using expression of all 28 measured proteins. 
Protein expression is shown on a common viSNE map for (C) pretreatment T-PLL and (D) 
post-treatment/relapse T-PLL. Color (for C and D) indicates the intensity of the labeled 
protein on a rainbow heat (ArcSinh) scales.
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Fig 5. 
Clinical resistance correlates with downregulation of CD45 protein, mRNA, and 
phosphatase activity. (A–C) Flow cytometry dot plots show (A) staining patterns of T-cell 
prolymphocytic leukemia (T-PLL) cells before (pre-RX) and after (post-RX) ruxolitinib 
treatment/relapse for forward scatter (FSC) and side scatter (SSC), 7-aminoactinomycin D 
(7-AAD), and anti-CD45. Three distinct populations were noted on the basis of CD45 
expression; (B) cells were flow sorted, extracted for genomic DNA, subjected to polymerase 
chain reaction for relevant exons, and sequenced. (C) Western blot analysis of pre-RX and 
post-RX/relapse T-PLL cells for total JAK1, JAK3, and AKT proteins. (D) RNA-seq results 
for PTPRC, JAK2, JAK3, JAK1, and TYK2. Vertical line separates pre-RX and post-RX/
relapse samples; both were analyzed in duplicate. Left panel, RPKM for T-PLL, reads per 
kilobase of gene per million reads; right panel, RPKM normalized to pre-RX reads (set at 
100%). (E) Bar graphs show measured in vitro phosphatase activity from cytosolic lysates 
prepared from T-PLL cells before (blue) and after (gold) ruxolitinib. The second set of 
assays was done after pull down with isotype control IgG/protein A/G. The third set of 
Greenplate et al. Page 20
JCO Precis Oncol. Author manuscript; available in PMC 2019 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
assays was done after incubation with anti-CD45/protein A/G; values were normalized to 
cytosolic lysates before immunodepletion (set at 100%); error bars show standard error of 
the mean from quadruplicates. (F) Graph shows a kinetic phosphatase assay of cytosolic 
lysates prepared from pre-RX and post-RX/relapse T-PLL cells. The x-axis shows varying 
concentrations of phosphatase substrate, DiFMUP (6, 8-difluoro-4-methylumbiliferyl 
phosphate), in micromolar; the y-axis, velocity of product formation in mRFU/min.
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Fig 6. 
T-cell prolymphocytic leukemia (T-PLL) cells have constitutive phospho-STAT1 (p-STAT1) 
and p-STAT5. Intracellular signaling responses, monitored by using phospho-flow 
cytometry, of peripheral-blood mononuclear cells (PBMCs) from healthy donors, and from 
the patient with T-PLL before (pretreatment) and after (post-treatment) relapse experienced 
during ruxolitinib treatment. (A) Biaxial plots show expression of CD45 and CD3 on healthy 
donor and T-PLL samples. Blue gates indicate populations defined by expression of CD45 
(hi, lo, and negative). CD3+ included peripheral T cells in health donor and all T-PLL cells. 
(B) Biaxial plots show basal p-STAT-1, p-STAT5, and p-STAT6 in CD3+ CD45hi cells. (C) 
Biaxial plot shows CD45 versus p-STAT5 and p-STAT6 at the time of relapse. Right panel, 
bar graph of percentage of cells with p-STAT5 or p-STAT6 for cells that express CD45hi, 
CD45lo, and CD45neg. (D) Graphs show p-STAT5 and p-STAT6 for health donor T cells, 
pretreatment T-PLL, and post-treatment T-PLL unstimulated or after 15 minutes of cytokine 
stimulation at 20 ng/mL.(E) Similar graphs of cytokine-stimulated p-STAT5 and p-STAT6 
for post-treatment T-PLL cells with CD45hi, CD45lo, or CD45neg gating. Values are from 
median fluorescent intensities that were ArcSinh transformed and expressed as a fold change 
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from the table’s minimum value. Graphs are shaded from black to yellow to reflect ratios 
from zero to four, as shown by the scale. Y-axes show counts, and x-axes show fluorescence.
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